Specific noncovalent interactions are commonly used by nature to modulate numerous processes including cell recognition, viral adhesion, and transmembrane communications. Here we report on the design, synthesis, and preliminary characterization of new supramolecular glycodendrimer-based hybrid drugs based on adamantyl-modified glycodendrimers of third, fourth, or fifth generation (mPPI-G3-AdaB, mPPI-G4-AdaB, and mPPI-G5-AdaB) and a new heterobifunctional ligand. This component was tailored to bind through noncovalent interactions both the multimeric natural 5-HT3 receptor (through an optimized arylpiperazine pharmacophore) and the adamantyl groups located on the glycodendrimer surfaces (through a β-cyclodextrin residue) giving rise to biorelevant supramolecular constructs. © 2014 American Chemical Society.

Paolino, M., Komber, H., Mennuni, L., Caselli, G., Appelhans, D., Voit, B., et al. (2014). Supramolecular Glycodendrimer-Based Hybrid Drugs. BIOMACROMOLECULES, 15(11), 3985-3993 [10.1021/bm501057d].

Supramolecular Glycodendrimer-Based Hybrid Drugs

Paolino, Marco;Cappelli, Andrea
2014-01-01

Abstract

Specific noncovalent interactions are commonly used by nature to modulate numerous processes including cell recognition, viral adhesion, and transmembrane communications. Here we report on the design, synthesis, and preliminary characterization of new supramolecular glycodendrimer-based hybrid drugs based on adamantyl-modified glycodendrimers of third, fourth, or fifth generation (mPPI-G3-AdaB, mPPI-G4-AdaB, and mPPI-G5-AdaB) and a new heterobifunctional ligand. This component was tailored to bind through noncovalent interactions both the multimeric natural 5-HT3 receptor (through an optimized arylpiperazine pharmacophore) and the adamantyl groups located on the glycodendrimer surfaces (through a β-cyclodextrin residue) giving rise to biorelevant supramolecular constructs. © 2014 American Chemical Society.
2014
Paolino, M., Komber, H., Mennuni, L., Caselli, G., Appelhans, D., Voit, B., et al. (2014). Supramolecular Glycodendrimer-Based Hybrid Drugs. BIOMACROMOLECULES, 15(11), 3985-3993 [10.1021/bm501057d].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/48805
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo